Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)

This product innovatively applies big data analysis to empower druggability research, and adopts innovative technologies with independent intellectual property rights as well as a highly stable pre-F antigen sequence. Preclinical studies have shown that this product can not only stimulate the body to produce high-titer neutralizing antibodies against both RSV A2 and B subtypes, but also activate a high-level cellular immune response. In cotton rat challenge protection studies, it was able to reduce the viral load in the lungs below the detection limit, exhibiting a significant protective effect. Furthermore, no vaccine-enhanced disease (VED) phenomenon was observed, indicating high safety. Meanwhile, the pre-F antigen structure contained in this product has excellent thermal stability—it does not require lyophilization and can be stored for a long time in a liquid state at 2~8℃. This optimizes the formulation production process, making subsequent commercial production more convenient and efficient.
This product obtained IND approval in China and the United States respectively in August 2025.

For all the above-mentioned products, we are seeking localized cooperation, technology transfer, and agency partnerships in overseas markets.